This week s Bioelectronic
Medicines Summit is one of a range of initiatives established by GSK in 2013 to stimulate research, recognizing that bioelectronics
development will require the combined skills of world-leading engineers, biologists, neuroscientists and informatics experts.
Corporation is a leader in Bioelectroceutical devices and the maker of an industry leading family of disposable, drug-free, anti-inflammatory devices: ActiPatch Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx Devices for chronic and post-operative wound care; HealFast Therapy for veterinary applications, Allay Menstrual Pain Therapy and Smart Insole(TM) Heel Pain Therapy.
plans to formally introduce its new back pain belt over the coming next few months, with shipments to international distributors beginning shortly thereafter.
Deepak Kotak, Executive VP of BioElectronics
, a Fellow of the Royal College of Anesthesiologists said, "Musculoskeletal pain is an increasing problem with few appropriate, safe, drug solutions.
we are aggressively moving into many international markets," Horev said.
We have assembled a substantial amount of compelling documentation to present to FDA that outlines not only the extreme safety of our products, but also the high level of efficacy," said Andrew Whelan, CEO of BioElectronics
We are pleased to have a market leader like Medikon handle both our retail products and wound and pain management product, RecoveryRx," said Erin Sanders, BioElectronics
For the past few months we have been working very hard to finalize our relationship with several Chinese partners, in conjunction with Project Asia, all of whom have a high level of interest in marketing the Allay product within the People's Republic of China," said Andrew Whelan, CEO of BioElectronics
Andrew Whelan, CEO of BioElectronics
provides the following update to investors and other stakeholders:
4, 2015 /PRNewswire/ -- BioElectronics
Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released analysis of its ongoing and second long term follow up survey of customers in the United Kingdom and Ireland who are managing chronic pain with ActiPatch Therapy, and reducing their dependence on systemic pain drugs.
announced today that a new audio interview with BioElectronics
Deepak Kotak, BioElectronics
Executive Vice President, said: "Providing effective analgesia and a reduced need for non-steroidal anti-inflammatory drugs and opioids is inherently safer, better tolerated and more cost-effective, particularly in an aging population.